Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) Research & Development (2016 - 2025)

vTv Therapeutics' Research & Development history spans 12 years, with the latest figure at $3.9 million for Q4 2025.

  • For Q4 2025, Research & Development rose 74.93% year-over-year to $3.9 million; the TTM value through Dec 2025 reached $17.9 million, up 54.69%, while the annual FY2025 figure was $17.9 million, 54.69% up from the prior year.
  • Research & Development for Q4 2025 was $3.9 million at vTv Therapeutics, down from $7.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $7.0 million in Q3 2025 and bottomed at $2.1 million in Q4 2023.
  • The 5-year median for Research & Development is $3.1 million (2021), against an average of $3.4 million.
  • The largest annual shift saw Research & Development tumbled 46.06% in 2023 before it soared 117.74% in 2025.
  • A 5-year view of Research & Development shows it stood at $5.4 million in 2021, then decreased by 26.62% to $4.0 million in 2022, then crashed by 46.06% to $2.1 million in 2023, then rose by 4.49% to $2.2 million in 2024, then skyrocketed by 74.93% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for VTVT's Research & Development are $3.9 million (Q4 2025), $7.0 million (Q3 2025), and $4.1 million (Q2 2025).